Abstract Number: 2891 • 2013 ACR/ARHP Annual Meeting
Loss Of Caspase 8 Exacerbates Dendritic Cell Activation In a MyD88- and RIPK1-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF3
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…Abstract Number: 2892 • 2013 ACR/ARHP Annual Meeting
Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis
Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and…Abstract Number: 2893 • 2013 ACR/ARHP Annual Meeting
Intestinal Microbiota Plays a Critical Role In The Production Of Antinuclear Antibodies In Lymphopenia-Induced Autoimmunity
Background/Purpose: Production of antinuclear autoantibodies (ANAs) is one of the major characteristics of the systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), but the…Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting
Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus
Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting
Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting
The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…Abstract Number: 2858 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chronic Pain By IL4-10 Synerkine Is Superior To IL-4 Or IL-10 Monotherapy: A Novel Strategy To Restrain Pain In Rheumatic Diseases
Background/Purpose: Chronic pain is a major problem in many diseases, including RA and OA, arising from inflammation or structural damage. It is often associated with glial…Abstract Number: 2859 • 2013 ACR/ARHP Annual Meeting
Pain Pathway Activation In Dorsal Root Ganglia and Dorsal Horn In a Murine Surgical Model Of Osteoarthritis
Background/Purpose: Using a surgical mouse model of osteoarthritis (OA), destabilization of the medial meniscus (DMM), we monitor pain and associated pathways over a period of…Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting
Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…Abstract Number: 2861 • 2013 ACR/ARHP Annual Meeting
Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Background/Purpose: Anti-Ro associated congenital heart block (CHB) exhibits a 33% concordance rate in monozygotic twins, 17.5% recurrence of disease and a high sibling risk ratio…Abstract Number: 2862 • 2013 ACR/ARHP Annual Meeting
Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE…Abstract Number: 2863 • 2013 ACR/ARHP Annual Meeting
Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is a systemic and inflammatory vasculopathy that affects mainly proximal muscles and skin in children. It is a rare but severe…Abstract Number: 2864 • 2013 ACR/ARHP Annual Meeting
Whole Exome Sequencing In Pediatric Patients With Early Onset Rare Immunodysregulatory Diseases That Present With Fever and Systemic Inflammation
Background/Purpose: WES (Whole Exome Sequencing) has increasingly become the tool of choice in translational research, providing molecular diagnoses in Mendelian diseases and identifying important genes…Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…Abstract Number: 2866 • 2013 ACR/ARHP Annual Meeting
Determining The Absolute Change In The Clinical Disease Activity Index (CDAI) To Define a Minimally Important Difference
Background/Purpose: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasing in use in clinical practice. However, the absolute minimally important difference (MID) in…